Literature DB >> 22571309

Colorectal cancer screening in Australia: a community-level perspective.

Ryan J Courtney1, Christine L Paul, Robert W Sanson-Fisher, Finlay A Macrae, Mariko L Carey, John R Attia, Mark A McEvoy.   

Abstract

OBJECTIVES: To determine current colorectal cancer (CRC) screening rates and the level of adherence to screening guidelines @a community level.
SETTING: A cross-sectional cohort of at-risk people aged 56-88 years randomly selected from the Hunter Community Study (HCS), Australia. MAIN OUTCOME MEASURES: Proportion ever reporting undertaking any CRC testing; current screening rates for each CRC screening modality; level of screening in accordance with national screening guidelines.
RESULTS: Of the 1117 participants (70%) who returned a questionnaire, 777 were deemed asymptomatic and eligible for analysis. Overall, 63% of respondents had ever received any CRC testing. Forty-three per cent had ever had a faecal occult blood test (20% screened in the previous 2 years); 30% had ever had a colonoscopy (16% screened in the previous 5 years); and 7% had ever had a sigmoidoscopy (1% screened in the previous 5 years). Rates of adherence to screening guidelines were 21% for respondents who were @or slightly above average risk, and 45% for respondents who were @moderately increased or potentially high risk.
CONCLUSIONS: Rates of CRC screening remain low. The screening rate for colonoscopy was particularly high among people who were @or slightly above average risk, despite such screening not being endorsed in the guidelines. Effective strategies to improve rates of CRC screening and appropriate use of colonoscopy are required across the entire at-risk population.

Entities:  

Mesh:

Year:  2012        PMID: 22571309     DOI: 10.5694/mja11.10661

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  6 in total

Review 1.  Screening participation for people at increased risk of colorectal cancer due to family history: a systematic review and meta-analysis.

Authors:  Driss Ait Ouakrim; Trevor Lockett; Alex Boussioutas; John L Hopper; Mark A Jenkins
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

2.  Screening practices of Australian men and women categorized as "at or slightly above average risk" of colorectal cancer.

Authors:  Driss Ait Ouakrim; Trevor Lockett; Alex Boussioutas; Louise Keogh; Louisa B Flander; Ingrid Winship; Graham G Giles; John L Hopper; Mark A Jenkins
Journal:  Cancer Causes Control       Date:  2012-09-26       Impact factor: 2.506

3.  Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios.

Authors:  Mary Dillon; Louisa Flander; Daniel D Buchanan; Finlay A Macrae; Jon D Emery; Ingrid M Winship; Alex Boussioutas; Graham G Giles; John L Hopper; Mark A Jenkins; Driss Ait Ouakrim
Journal:  PLoS Med       Date:  2018-08-16       Impact factor: 11.069

4.  Does self-reported symptom questionnaire play a role in nonadherence to colonoscopy for risk-increased population in the Tianjin colorectal cancer screening programme?

Authors:  Lizhong Zhao; Xiaorui Zhang; Yongjie Chen; Yuan Wang; Weihua Zhang; Wenli Lu
Journal:  BMC Gastroenterol       Date:  2021-03-09       Impact factor: 3.067

5.  A population-based cross-sectional study of colorectal cancer screening practices of first-degree relatives of colorectal cancer patients.

Authors:  Ryan J Courtney; Christine L Paul; Mariko L Carey; Robert W Sanson-Fisher; Finlay A Macrae; Catherine D'Este; David Hill; Daniel Barker; Jody Simmons
Journal:  BMC Cancer       Date:  2013-01-10       Impact factor: 4.430

6.  Can a print-based intervention increase screening for first degree relatives of people with colorectal cancer? A randomised controlled trial.

Authors:  Mariko Carey; Robert Sanson-Fisher; Finlay Macrae; Emilie Cameron; David Hill; Catherine D'Este; Jody Simmons; Christopher Doran
Journal:  Aust N Z J Public Health       Date:  2016-09-13       Impact factor: 2.939

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.